Validated green high‐performance liquid chromatographic methods for the determination of coformulated pharmaceuticals: A comparison with reported conventional methods

Q3 · CHEMISTRY

Article

Author: Salem, Maissa Y. ; Abd El Fattah, Laila E. ; Elzanfaly, Eman S. ; Saad, Samah S. ; Hegazy, Maha A.

The introduction of sustainable development concepts to analytical laboratories has recently gained interest, however, most conventional high‐performance liquid chromatography methods do not consider either the effect of the used chemicals or the amount of produced waste on the environment. The aim of this work was to prove that conventional methods can be replaced by greener ones with the same analytical parameters. The suggested methods were designed so that they neither use nor produce harmful chemicals and produce minimum waste to be used in routine analysis without harming the environment. This was achieved by using green mobile phases and short run times. Four mixtures were chosen as models for this study; clidinium bromide/chlordiazepoxide hydrochloride, phenobarbitone/pipenzolate bromide, mebeverine hydrochloride/sulpiride, and chlorphenoxamine hydrochloride/caffeine/8‐chlorotheophylline either in their bulk powder or in their dosage forms. The methods were validated with respect to linearity, precision, accuracy, system suitability, and robustness. The developed methods were compared to the reported conventional high‐performance liquid chromatography methods regarding their greenness profile. The suggested methods were found to be greener and more time‐ and solvent‐saving than the reported ones; hence they can be used for routine analysis of the studied mixtures without harming the environment.

01 Sep 2006·Diabetes Care

Exposure to Rosiglitazone and Fluoxetine in the First Trimester of Pregnancy

Letter

Author: Shin, Joong-Sik ; Yang, Jae-Hyug ; Nava-Ocampo, Alejandro A. ; Choi, June-Seek ; Han, Jung-Yeol ; Ahn, Hyun-Kyong ; Koong, Mi-Kyoung

Rosiglitazone is a thiazolidinedione oral hypoglycemic drug that seems to be a promising alternative not only as an oral hypoglycemic agent but also for women with polycystic ovary syndrome. However, information regarding exposure to rosiglitazone in pregnancy is limited to two previous case reports. In the first case, a 35-year-old woman was exposed until the 8th week of pregnancy to 4 mg/day rosiglitazone and to glicazide, acarbose, atorvastatin, spironolactone, hydrochlorothiazide, carbamazepine, thiridazine, amitryptiline, chlordiazepoxide, and pipenzolate bromide (1). The second case was a woman exposed to 4 mg/day rosiglitazone between gestational weeks 13 and 17 (2). The two cases delivered normal babies at gestational weeks 36 and 37, …

01 Jun 2004·Reproductive ToxicologyQ4 · MEDICINE

Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman

Q4 · MEDICINE

Article

Author: Nuri Ihsan Kalyoncu ; Murat Kesim ; Ersin Yaris ; Mine Kadioglu ; Cunay Ulku ; Fusun Yaris

The subject is a diabetic and hypertensive woman treated early during an unplanned pregnancy with a multi-drug regimen that included three drugs with no prior history for use in pregnant women (rosiglitazone, gliclazide, atorvastatin). She was under care for chronic hypertension, which she suffered for 14 years, and diabetes mellitus, hypercholesterolemia, anxiety disorder, morbid obesity and epilepsia for 5 years. She was exposed to rosiglitazone (4mg/day), gliclazide (60mg/day), and atorvastatin (40mg/day) in addition to acarbose, spironolactone, hydrochlorothiazide, carbamazepine, thioridazine, amitryptiline, chlordiazepoxide, and pipenzolate bromide during the first 7 weeks of gestation while unaware of pregnancy. Pharmacotherapy was adjusted following clinical recognition of pregnancy during the 8th week. She gave birth to a normal healthy infant at the 36th week of gestation. This is the first reported case of human exposure to rosiglitazone, gliclazide, and atorvastatin during pregnancy. Although the normal pregnancy outcome does not address the safety of these drugs for use in pregnancy, these data contribute to a limited knowledge regarding human exposure to these antidiabetic drugs.

100 Deals associated with Pipenzolate Bromide

External Link

KEGG	Wiki	ATC	Drug Bank
D07084	Pipenzolate Bromide	A03AB14	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Spasm	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis